Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $27K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $113K.
Context
- Cost of revenue amounted to 0.5% of revenue in FY2025.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near $27K or moves back toward the trailing-twelve-month quarterly average of $28.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 325K USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 325K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 437K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.4% is the 5th highest of 8, against a peer median of +31.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.94M USD | — | — | 77.7% | |
| LTM Mar 2026 | $10.68M USD | +89.7% | — | 18096.6% | |
| LTM Mar 2026 | $6.99M USD | +800.8% | +50.4% | 48.1% | |
| LTM Mar 2026 | $3.96M USD | +31.7% | +252.4% | 7.8% | |
| FY2025 | €2.8M EUR | -28.0% | +41.1% | 62.4% | |
| LTM Mar 2026 | $1.95M USD | -96.9% | +0.0% | 17.4% | |
| LTM Mar 2026 | $1.21M USD | — | — | 1.7% | |
| LTM Mar 2026 | $793.21K USD | +354.2% | +64.1% | — | |
| LTM Mar 2026 | $113K USD | +31.4% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | -$101K USD | -104.8% | -1.1% | 44.9% | |
| Peer median (excluding BDTX) | — | +31.7% | +45.8% | 46.5% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70M |
| Cost of Revenue | 0 | 0 | 437K | 0 | 325K |
| Gross Profit | 0 | 0 | (437K) | 0 | 69.68M |
| Gross Margin | — | — | — | — | 99.5% |
| Research & Development | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M |
| Selling, General & Admin | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M |
| Operating Expenses | 126.87M | 92.83M | 86.02M | 78.78M | 49.81M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| EBITDA | (125.39M) | (90.66M) | (82.01M) | (69.33M) | 22.69M |
| EBITDA Margin | — | — | — | — | 32.4% |
| Operating Income | (126.87M) | (92.83M) | (86.46M) | (78.78M) | 19.87M |
| Operating Margin | — | — | — | — | 28.4% |
| Interest Income | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M |
| Income Before Tax | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Pre-Tax Margin | — | — | — | — | 32.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Net Margin | — | — | — | — | 32.0% |
| EPS (Basic) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| EPS (Diluted) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| Weighted Avg Shares | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M |
| Weighted Avg Shares (Diluted) | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.